What would strengthen IbogaBase

Named reviewers — still open (red)

Independent named review seats are not filled. No medical, cultural, or legal reviewer is listed as having accepted scope-limited review. Until that changes, pages should be read as source-compiled public reference, not expert endorsement. Outreach is paused pending owner decision — this page does not invite or contact reviewers.

• Medical / toxicology — mortality and adverse-event language bounds.
• Cardiology (QT/QTc-aware) — cardiac-risk framing without under- or over-statement.
• Addiction psychiatry / medicine — OUD/AUD evidence grades vs media cure language.
• Trauma / PTSD research — veteran-media claims vs observational study limits.
• Gabonese / Bwiti cultural steward–scholar — public-vs-private knowledge boundary (consent-first).
• Drug-policy / controlled-substances law — Schedule I vs state-bill accuracy; not legal advice.
• Librarian / information scientist — citation hygiene and catalog discipline.

Related process notes live on Standards and Methodology. Reviewer names appear only with consent.

Evidence and safety gaps

• Many condition pages remain observational- or media-heavy; randomized clinical evidence for ibogaine in humans is still limited.
• Mortality denominators and clinic-reported “success rates” need ongoing source discipline — numerators without denominators stay weak.
• DIY / self-treatment refusal is policy; the site will not add protocols, dosing, or referrals to close a “coverage” gap.

Catalog and link hygiene

• Listening Library: one outbound URL remains dead-flagged (Clare Wilkins / ibogaineconference.org). No invented replacement.
• Full sources catalog inline expansion vs dedicated citation-hygiene pages — prefer verified citations over volume.
• Trial registry rows should stay tied to working ClinicalTrials.gov NCT links and labeled status dates.

See Listening Library verify status, Trials, and Citation hygiene.

Culture and law gaps

• Culture desk coverage from outsider secondary sources cannot substitute for steward review of public-boundary language.
• State-bill trackers need periodic re-check against primary bill text; funding politics ≠ Schedule I repeal or FDA approval.

What this page is not

• Not a claim of best-in-field status or Jev ≥ 3.5.
• Not medical advice, legal advice, dosing guidance, or clinic referral.
• Not a reviewer call-for-proposals or outreach list for public contact.